MedTrace Logo

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

NCT00003954 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-02-06

No results posted yet for this study

Summary

In this study donor bone marrow transplantation is divided into a two step process to try to significantly reduce the side effects of the procedure yet still provide patients with multiple myeloma the benefits of this procedure

Conditions

  • Refractory Multiple Myeloma
  • Stage I Multiple Myeloma
  • Stage II Multiple Myeloma
  • Stage III Multiple Myeloma

Interventions

DRUG

melphalan

Given IV

PROCEDURE

autologous hematopoietic stem cell transplantation

Undergo autologous bone marrow or PBSCT

PROCEDURE

autologous bone marrow transplantation

Undergo autologous bone marrow or PBSCT

PROCEDURE

peripheral blood stem cell transplantation

Undergo autologous bone marrow or PBSCT

RADIATION

total-body irradiation

Undergo TBI

PROCEDURE

peripheral blood stem cell transplantation

Undergo donor PBSCT

DRUG

cyclosporine

Given IV and PO

DRUG

mycophenolate mofetil

Given PO

BIOLOGICAL

therapeutic allogeneic lymphocytes

Undergo DLI

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • David Maloney · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31
Primary Completion
2002-12-31

Countries

  • United States
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003954 on ClinicalTrials.gov